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Abstract The importance of TNF-α signals mediated by
tumor necrosis factor receptor type 1 (TNFR1) in inflam-
mation and fibrosis induced by carbon tetrachloride (CCl4),
and in post-injury liver regeneration including a GFP/CCl4
model developed as a liver repair model by bone marrow
cell (BMC) infusion, was investigated. In mice in which
TNFR1 was suppressed by antagonist administration or by
knockout, liver fibrosis induced by CCl4 was significantly
decreased. In these mice, intrahepatic macrophage infiltra-
tion and TGF-β1 expression were reduced and stellate cell
activity was decreased; however, expression of MMP-9 was
also decreased. With GFP-positive BMC (TNFR1 wild-
type, WT) infusion in these mice, fibrosis proliferation,
including host endogenous intrahepatic macrophage infil-
tration, TGF-β1 expression and stellate cell activity,
increased significantly. There was no significant increase
of MMP-9 expression. In this study, TNFR1 in hosts had a
promoting effect on CCl4-induced hepatotoxicity and
fibrosis, whereas BMC infusion in TNFR1 knockout mice
enhanced host-derived intrahepatic inflammation and
fibrosis proliferation. These findings differed from those
in WT recipient mice, in which improvement in
inflammation and fibrosis with BMC infusion had
previously been reported. TNFR1-mediated signaling
might be important to induce the improvement of liver
fibrosis by bone marrow cell infusion.
Keywords Tumor necrosis factor.CCl4.Bone marrow
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Introduction
The mechanism of hepatotoxicity induced by many factors,
including CCl4, has been studied for a long time (Drill
1952) and besides direct cytotoxicity due to these factors,
enhanced hepatotoxicity due to inflammatory cell infiltra-
tion and stellate cell activation induced by these factors also
occurs. TNF-α is an important inflammatory cytokine that
induces hepatotoxicity; however, it also initiates liver
regeneration after injury. This has been examined in various
previous hepatotoxicity, hepatic resection and hepatic
failure models. In addition, in recent stem cell studies,
TNF-α signals have been found to be essential in the
differentiation/proliferation process from stem cells to
functional cells. For effective expression of TNF-α signals,
of the various receptors, TNFR1 (p55) is important. In
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of hepatotoxicity has been shown, decreased liver regener-
ation and hepatocyte proliferation have also been confirmed
(Gardner et al. 2003; Simeonova et al. 2001; Sudo et al.
2005; Yamada and Fausto 1998).
In our laboratory, using a GFP/CCl4 model, BMC
infusion has been shown to improve fibrosis and liver
function in cirrhosis (Sakaida et al. 2004, 2008; Terai et al.
2002, 2005). In the liver of mice not treated with CCl4,
without hepatic toxicity, repopulation of GFP-positive
BMCs into the liver has not been observed, thus highlight-
ing the need for chronic inflammatory signals in cell
repopulation and effective expression. In addition, after
BMC infusion, alterations in TNFR1 expression and
associated increases in various cytokines such as fibroblast
growth factor 2 (FGF2) have been recognized (Omori et al.
2004). This also suggested the importance of inflammato-
ry signals, particularly TNF-α signals, in liver function
improvement. Therefore, to investigate the importance of
TNF-α signals mediated by TNFR1 in liver repair by
BMC infusion in recipients, this study using TNFR1
antagonist-administered mice and TNFR1 KO mice as
recipients was conducted.
Materials and methods
Mice
C57BL/6 TNFR1 KO mice were kindly provided by
Hiroshi Nishina (Department of Developmental and
Regenerative Biology, Medical Research Institute, Tokyo
Medical and Dental University). TNFR1 KO mouse
typing was performed by PCR analysis using primer
typing box [p55R636 and HSV-TK (to confirm induc-
tion of silencing gene factor)]. Those primers were
p55R636 (5′-GGCTGCAGTCCACGCACTGG-3′), and
HSV-TK (5′-ATTCGCCAATGACAAGACGCTGG-3′)
(data not shown) (Pfeffer et al. 1993). C57BL/6 female
mice were purchased from Chiyoda SLC (Tokyo, Japan).
GFP-transgenic mice (TgN(β-act-EGFP)Osb) were kindly
provided by Masaru Okabe (Genome Research Center,
Osaka University, Osaka, Japan). These mice were
maintained in specific pathogen-free housing at the
Animal Experiment Facility of Yamaguchi University
School of Medicine and cared for in accordance with the
animal ethics requirements at Yamaguchi University
School of Medicine.
Experimental protocol
First, to confirm that signals mediated by TNFR1 are
important in intrahepatic inflammatory responses and
fibrosis induced by CCl4, an experiment using TNFR1
antagonist (anti-mouse TNFR1 antibody, MAB430; R&D
Systems, Minneapolis, MN, USA) was conducted in wild-
type (WT) mice. In WT mice, CCl4 was administered for
4 weeks to create a liver cirrhosis model; then, by caudal
vein injection of 100 μg/body of antagonist, signals
mediated by TNFR1 were suppressed in recipients; and
thereafter, CCl4 was continued for 1 week. A model was
also created with infusion of GFP-positive BMCs after
1 h, when in vivo activity of the antagonist reaches a peak.
There were 3 groups: WT (Control) (wild-type, without
BMC infusion); WT+A (wild-type, with TNFR1 antago-
nist only, without BMC infusion); and GFP/WT+A (wild-
type, with TNFR1 antagonist and with BMC infusion)
(Fig. 1).
As will be described later, by blocking TNFR1,
suppression of fibrosis and suppression of inflammatory
cell infiltration were confirmed. Therefore, as a more highly
specific model, a model was created by the following
protocol with TNFR1 KO mice as BMC infusion recipients.
Six-week-old female C57BL/6 mice and female iso-
genic TNFR1 KO mice were treated with CCl4 (1.0 ml/kg
body diluted 1:3 in corn oil) twice a week for 8 weeks. In
the other group, after 4 weeks of CCl4 administration in
each group (C57BL/6 wild-type and TNFR1 KO), bone
marrow cells (BMC) (1×10
5 cells) from GFP transgenic
mice were injected via the tail vein as previously described
(Terai et al. 2003).
After 8 weeks, 36 h after the last CCl4 injection, the
mice were sacrificed to examine the blood data and liver
tissue specimens. The liver was fixed in 4% buffered
paraformaldehyde for 24–48 h and paraffin embedded.
Blood samples were obtained by cardiac puncture and
drawn into a glass tube containing 7.5% EDTA (pH 7.4).
After centrifugal separation, the plasma was stored at 4°C.
There was a total of 4 groups in this study: WT
(Control), wild-type without BMC infusion; KO (Control),
TNFR1 KO without BMC infusion; GFP/WT, wild-type
with GFP-positive BMC infusion; and GFP/KO, TNFR1
KO with GFP-positive BMC infusion (Fig. 1).
Quantitative analysis of liver fibrosis and
immunohistochemistry
The liver fibrosis area was quantified with Sirius-red
staining using an Olympus Provis microscope equipped
with a CCD camera (Olympus, Tokyo, Japan). The red
area, considered the fibrotic area, was assessed by
computer-assisted image analysis with MetaMorph soft-
ware (Universal Imaging, Downingtown, PA, USA) at a
magnification of ×40. The mean value of 10 randomly
selected areas per sample was used as the expressed
percent area of fibrosis.
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actin (α-SMA), matrix metalloproteinase (MMP)-9
and F4/80
Three-μm-thick liver sections were mounted on microscope
slides, routinely dewaxed and rehydrated and pretreated
with Vector Antigen Unmasking Solutions (Citrate-based,
Cat. No. H-3300). For the immunohistochemical analysis,
the Vectastain ABC kit (Vector Laboratories, Burlingame,
CA, USA) was used for GFP (anti-GFP, rabbit IgG fraction,
A11122; Invitrogen, Carlsbad, CA, USA), TGF-β1[TGF-
β1(V), SC-146; Santa Cruz Biotechnology], alpha-smooth
muscle actin (α-SMA) (alpha smooth muscle actin anti-
body, ab6594; Abcam, Cambridge, MA, USA), matrix
metalloproteinase (MMP)-9 (anti-mouse MMP-9 antibody,
AF909; R&D Systems) and F4/80 [F4/80 antibody(BM8),
ab16911; Abcam] staining by the avidin-biotin-peroxidase
complex method.
Additionally, double immunofluorescent staining was
performed to study co-expression of GFP and F4/80 in
bone marrow cell-infused mice. The mixture of the first
antibodies was GFP and F4/80 noted above. The
secondary antibodies, goat anti-rabbit IgG (H+L), Alexa
Fluor 488 (A11034,;Invitrogen) (Green) and goat anti-
rat IgG (H+L), Alexa Fluor 568 (A11077; Invitrogen)
(Red) were each applied at a concentration of 1:400 in
PBS for 60 min at room temperature. Before attaching
the coverslip, DAPI (D212; Dojindo Laboratories,
Kumamoto, Japan) was applied for counterstaining to
visualize all nuclei in the tissue sections. The sections
were viewed and photographed with the CCD camera
noted above.
Fig. 1 Experimental protocols. Protocol I In each group of mice, CCl4
(1.0 ml/kg body) was administered twice a week for 5 weeks to create a
liver cirrhosis model. In WT+A mice, 100 μg/body of TNFR1
antagonist was injected via tail vein before 1 week of sacrifice. GFP/
WT+A mice were treated with GFP positive BMC (1×10
5 cells)
infusion via tail vein 1 hour after TNFR1 antagonist injection. Protocol
II WT (Control) mice and KO (Control) mice were treated with CCl4
(same as above) for 8 weeks. In GFP/WT mice and GFP/KO mice, after
4 weeks of CCl4 administration, BMCs (1×10
5 cells) were injected,
followed by 4 weeks of CCl4 treatment
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Total RNAwas isolated from the livers of the mice treated at
4 weeks after the BMC infusion or control CCl4 treatment.
The messenger RNA (mRNA) expressions of TGF-β1a n d
MMP-9 were evaluated using real-time quantitative PCR.
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). For cDNA synthesis, AMV
reverse transcription reagents were used according to the
manufacturer’s instructions (Roche Diagnostic, Pleasanton,
CA, USA). Real-time PCR was performed with SYBR
Green Master Mix (Roche Diagnostic). The primers used for
TGF-β1w e r e5 ′-GAAGCCATCCGTGGCCAGAT-3′ (for-
ward) and 5′-GACGTCAAAAGACAGCACT-3′ (reverse),
for MMP-9 were 5′-GGAACTCACACGACATCTTCCA-3′
(forward) and 5′-GAAACTCACACGCCAGAAGAATTT-3′
(reverse) and collagen type 1 alpha were 5′-CGGGCAG
GACTTGGGTA-3′ (forward) and 5′-CGGAATCT
GAATGGTCTGACT-3′ (reverse). The PCR primers used
for mouse glyceraldehyde-3-phospatase dehydrogenase
(GAPDH), which was used as an internal control, were: 5′-
GTCTTCACCACCATGGAGAAGGC-3′,5 ′-ATG
CCAGTGAGCTTCCCGTTCAGC-3′. The cycle for PCR
was as follows: 1 cycle of 95°C for 20 s; 40 cycles of 3 s at
95°C and 30 s at 60°C; and 1 cycle of 95°C for 15 s, 60°C
for 1 min, and 95°C for 15 s. Reactions were performed in a
Step One Plus™ real-time PCR system (Applied Biosys-
tems, California, CA, USA) and amounts of all mRNAs
were quantified using StepOne™ version 2.1 software
(Applied Biosystems).
Western blot analysis
The liver samples (approximately 40 mg) were homoge-
nized in 1 ml of cell lysis buffer (Cell Signal Technology,
Beverly, MA, USA) and 1 mM phenylmethanesulfonyl
fluoride (PMSF) and complete mini-centrifuged (Roche
Diagnostic). The supernatant represented the whole protein.
Then, 40 μg of the protein sample were mixed with the
same volume of loading buffer (5% 2-mercaptoethanol and
95% Laemmli Sample Buffer; Bio-Rad Laboratories,
Hercules, CA, USA), heated for 4 min at 97°C and
separated by 10% SDS-PAGE. The separated bands were
transferred to Immobilon-P transfer membrane (Millipore,
Billerica, MA, USA), followed by blocking of the
membranes for 1 h with blocking buffer (0.1% Tween-20;
Wako Pure Chemical Industries, Osaka, Japan), 0.2% I-
Block™ reagent (Tropix, Bedford, MA, USA) and 1 mM
Tris-HCl buffer (pH 7.5) (Invitrogen). The membranes were
then washed with washing buffer (0.1% Tween-20, 1 mM
Tris-HCl buffer; pH 7.5) and incubated overnight at 4°C
with the primary antibodies against MMP-9 (R&D Sytems),
TGF-β1 (Santa Cruz Biotechnology) and β-actin (Abcam)
in blocking buffer. Then, after being washed, the mem-
branes were incubated for 1 h at room temperature with the
appropriate secondary antibodies. Reactive bands were
identified using ECL (Amersham Biosciences, Piscataway,
NJ, USA) and autoradiography, according to the manufac-
turer’s instructions.
Statistical analysis
Statistical significance was determined using 2-tailed
Student'st test. Results are presented as the mean±standard
deviation and differences of p<0.05 were considered
significant.
Results
Alterations of liver fibrosis and intrahepatic inflammatory
invasion by TNFR1 antagonist and BMC infusion
At 1 week after TNFR1 antagonist administration in wild-
type mice, liver fibrosis was significantly suppressed [WT
(Control): WT+A, p<0.01] in the antagonist-treated group
compared to the untreated group. In addition, F4/80-
positive intrahepatic macrophage infiltration tended to be
suppressed [WT (Control): WT+A, p=0.07] and stellate
cell activity, shown by α-SMA staining, was significantly
suppressed [WT (Control): WT+A, p<0.01]. However, in
the group with GFP-positive BMC infusion in addition to
the antagonist, liver fibrosis did not improve with BMC
infusion (WT+A: GFP/WT+A, p=0.44) Conversely, both
macrophage infiltration (WT+A: GFP/WT+A, p=0.02)
and stellate cell activity (WT+A: GFP/WT+A, p<0.01)
increased significantly (Fig. 2a–l).
Liver fibrosis did not improve in the KO recipient model
The migration of GFP positive cells was confirmed
using immunohistochemistry of GFP (Fig. 3a, b). On
Sirius red staining, liver fibrosis was significantly sup-
pressed in KO (Control) mice compared to WT (Control)
mice [WT (Control): KO (Control), p<0.05]. WT mice
tended to have strong fibrosis but similar to the GFP/CCl4
model that we previously reported (Terai, et al. 2003),
with BMC infusion, fibrosis improved significantly [WT
(Control): GFP/WT, p<0.01]. However, in TNFR1 KO
mice, in whom fibrosis was suppressed, BMC infusion did
not improve liver fibrosis [KO (Control): GFP/KO, p =
0.91] (Fig. 3c–g).
In addition, on real-time RT-PCR for collagen I-α1, in
WT mice, fibrosis proliferation was increased and in KO
mice, it was suppressed [WT (Control): KO (Control), p<
0.05]. In WT mice, as in our previous GFP/CCl4 model,
82 Cell Tissue Res (2011) 346:79–88after BMC infusion, collagen I-α1 mRNA expression was
decreased [WT (Control): GFP/WT, p<0.05]. On the other
hand, there were no changes in KO mice with BMC
infusion [KO (Control): GFP/KO, p=0.67] (Fig. 3h).
Fibrolytic reactions induced by BMC infusion
Expression of MMP-9, important in liver fibrosis improve-
ment, corresponded with sites of inflammation and fibrosis
in each model and based on western blot and real-time RT-
PCR analysis, MMP-9 expression was significantly sup-
pressed in KO mice compared to wild-type mice [WT
(Control): KO(Control), p<0.01]. However, in KO mice,
even with GFP-positive BMC infusion, there was no
significant increase, statistically proven in Real-time RT-
PCR analysis [KO (Control): GFP/KO, p=0.41]. This
showed that, in KO mice, although MMP-9 expression is
suppressed, BMC infusion in these mice did not clearly
increase MMP-9 (Fig. 3i-n).
Alterations of F4/80 positive cells into TNFR1 KO mice
In KO (Control) mice, compared to WT (Control) mice,
intrahepatic infiltration of F4/80-positive cells (macro-
phages) induced by CCl4 was significantly suppressed
[WT (Control): KO (Control), p<0.01] but with BMC
infusion, this infiltration was significantly increased [KO
(Control): GFP/KO, p<0.01] (Fig. 4a–e). Upon evaluation
of macrophage origin, in double immunofluorescent stain-
ing (GFP: emitting green light, and F4/80: emitting red
light), no cells showed co-positivity with GFP and F4/80. It
was indicated that the increased F4/80-positive macro-
Fig. 2 Suppression of liver fibrosis, hepatic stellate cell activation and
F4/80 positive cell invasion using TNFR1 antagonist. a–c Sirius red
staining of liver sections (original magnifications ×40). d Statistical
analysis of fibrotic area by the staining. Scale bars standard
deviations. WT liver (a) had severe fibrosis but WT+A liver (b) and
GFP/WT+A liver (c) did not. There was no significant improvement
induced by BMC infusion with TNFR1 antagonist. e–g Immunohis-
tochemistry of F4/80 (original magnifications ×100). h Statistical
analysis of F4/80 positive area. Comparing WT (e) with WT+A (f),
TNFR1 antagonist suppressed the invasion of F4/80 positive cells into
the liver but in GFP/WT+A (g), the invasion increased. i–k
Immunohistochemistry of α-SMA (original magnifications ×40).
l Statistical analysis of α-SMA positive area. Comparing WT (i) with
WT+A (j), TNFR1 antagonist suppressed the expression of α-SMA
but in GFP/WT+A (k), the bone marrow cell infusion raised the
activation regardless of TNFR1 antagonist administration
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of recipient pre-existing cells (Fig. 4f).
Upregulation of TGF-β1 signals and hepatic stellate cell
activation
Upon evaluation by immunostaining, TGF-β1 expression
was decreased in KO (Control) mice but after BMC
infusion, it was significantly increased (Fig. 4g–j). On
real-time RT-PCR analysis as well, in KO mice, TGF-β1
increased after BMC infusion [KO (Control): GFP/KO, p<
0.05] (Fig. 4k). On western blot analysis, the findings were
similar (Fig. 4l). With alterations in TGF-β1 expression,
stellate cell activity, evaluated by α-SMA staining, was
suppressed in KO (Control) mice but with BMC infusion,
in GFP/KO mice, it was significantly increased [KO
(Control): GFP/KO, p<0.05] (Fig. 4m–p).
Discussion
TNF-α has long been known as an inflammatory cytokine
whose action is mediated mainly by TNFR1. In addition to
TNFR1, several other receptors exist, including TNFR2,
each with a variety of actions, including cytotoxic effects,
cell proliferation and protective effects. TNFR1 itself is
known to be involved in various actions, including
induction of hepatocyte apoptosis, extracellular matrix
proliferation via downstream signals, anti-apoptosis effects
and hepatocyte proliferation. In a previous partial hepatec-
tomy model, the importance of TNF-α in liver regeneration
was demonstrated (Yamada et al. 1997) but on the other
hand, in studies using hepatotoxic factors such as CCl4 and
LPS, the involvement of TNF-α–TNFR1 pathways in the
enhancement of liver cell injury and fibrosis has often been
reported (Simeonova et al. 2001; Sudo et al. 2005; Horn et
al. 2000). For applications of these findings to clinical liver
disease, studies using TNFR1 knockout models, anti-TNF-
α neutralizing antibodies and anti-TNFR1 antagonists have
been conducted. Reductions in liver injury and liver fibrosis
have been reported (Haak-Frendscho et al. 1994; Inui et al.
2005; Shibata et al. 2008a).
In the GFP/CCl4 model, we reported that BMC infusion
has liver repair effects and improves liver fibrosis (Terai et
al. 2003). In reports to date from our laboratory, we have
shown that inflammatory cytokines induced by CCl4,
primarily TNF-α, are important in BMC survival and liver
repair (Omori et al. 2004). In addition, at other facilities, in
vitro models have shown the importance of TNF-α signals
in the differentiation of bone marrow stem cells to
functional cells. There are various theories about BMC
kinetics when infused in vivo (Higashiyama et al. 2007;
Dalakas et al. 2009; Terai and Sakaida 2008; Khurana and
Mukhopadhyay 2007) but much remains unknown.
In our study, to first confirm the effects of TNFR1, a
TNFR1 antagonist was used. Because TNFR1 antagonists
differ from anti-TNF-α antibodies, only block TNFR1, and
do not affect other signal pathways such as TNFR2
(Shibata et al. 2008b), administration of a sufficient dose
of antagonist in wild-type mice can reproduce a TNFR1
KO mouse system. A dose of 100 μg/body is sufficient to
enable inhibition of intrahepatic inflammatory responses
and liver fibrosis (Shibata et al. 2008a). Furthermore, the
in vivo half-life of an intravenously administered TNFR1
antagonist is 5–6 days (Haak-Frendscho et al. 1994), so
the blocking effect of TNFR1, up to the time of tissue
sampling after 1 week, as used in the present protocol,
probably continued.
In mice administered with the TNFR1 antagonist, intra-
hepatic macrophage infiltration was suppressed and stellate
cell activation was decreased. Studies in liver injury suppres-
sion models, by inhibition of TNFα-TNFR1 signals, not only
with TNFR1 antagonists but also with anti-TNF-α antibodies,
have been reported by several facilities (Sudo et al. 2005;
Yamada and Fausto 1998; Shibata et al. 2008a;K i t a m u r ae t
al. 2002; Bahcecioglu et al. 2008). In the present study as
well, in a model of advanced liver fibrosis induced by CCl4
administration in wild-type mice, the TNFR1 antagonist
suppressed intrahepatic inflammatory cell infiltration and
improved liver fibrosis. However, in this model, with
combined GFP-positive BMC infusion, intrahepatic inflam-
matory cell infiltration and stellate cell activation, which were
suppressed by the antagonist, worsened with BMC infusion
(attenuation of the suppression effect).
Next, to further clarify this phenomenon, TNFR1 KO
mice were used as recipients to investigate whether there
were differences in liver repair with BMC infusion based
on the presence or absence of TNFR1. In GFP/KO mice,
using TNFR1 KO mice as recipients, no liver repair effects
with BMC infusion were observed. In TNFR1 KO mice,
Fig. 3 Comparison of liver fibrosis using TNFR1 KO mice. a, b anti-
GFP immunohistochemistry (original magnifications, ×200). Both in
wild type mouse live (a) and in TNFR1 KO mouse liver (b), the
migrations of GFP positive bone marrow cells were confirmed. c–f
Sirius red staining of liver sections (original magnifications, ×40). g
Statistical analysis of fibrotic area. Scale bars standard deviations.
Compared with WT (Control) (c), GFP/WT (d) had marked fibrolysis.
KO (Control) (e) had significantly suppressed fibrosis but there was
no marked improvement of fibrosis in GFP/KO (f). h Real-time RT-
PCR analysis of expression of collagen type 1 alpha-1, indicating the
fibrotic activity, showed similar results. i–l Immunohistochemistry of
MMP-9 in liver sections (original magnifications, ×200). Liver section
of WT (Control) (i) [magnified figure (×400) (j)] had certain degree of
expression but in KO (Control) liver (k) and in GFP/KO liver (l), the
expression was significantly low level. m Real-time RT-PCR analyses.
n Western blot analyses of MMP-9; both showed suppression in
TNFR1 KO mice but no significant increase in GFP/KO mice was
seen and the suppression remained

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totoxicity and liver fibrosis were suppressed, GFP-positive
BMC infusion showed no synergism in liver repair or anti-
hepatotoxic effects.
The importance of an increase in hepatic expression of
MMP-9 by BMC infusion in liver fibrosis improvement has
been reported by many facilities, including our laboratory
(Sakaida et al. 2004, 2008; Higashiyama et al. 2007; Alwayn
et al. 2008). In the present study, MMP-9 expression was
markedly suppressed in TNFR1 KO mice compared to wild-
type mice. MMP-9 expression has been shown to increase by
TNF-α signals mediated via TNFR1 (Robinson et al. 2002;
Vaday et al. 2001). In TNFR1 KO mice, the fact that this was
suppressed is a consistent finding. In our laboratory, GFP-
positive BMC infusion in wild-type mice was reported to
enhance hepatic expression of MMP-9 (Sakaida et al. 2004).
Within this series of cascades, inflammatory signals such as
TNFR1 have been shown to be important (Omori et al.
2004). On the other hand, in GFP/KO mice, in which GFP-
positive BMCs were infused in TNFR1 KO mice, there was
no significant increase in MMP-9 expression and, moreover,
the amount of expression compared to wild-type mice was
significantly decreased, with no demonstrable effect on liver
fibrolysis. With regard to the origin of MMP-9, infused
BMCs have received attention but signals mediated by
TNFR1 in pre-existing hepatocytes and host-derived hepatic
macrophages are also important (Haruyama et al. 2000).
These are suppressed in KO mice; furthermore, an increase
in cytokine groups, such as increased TGF-β1 expression,
which conversely suppresses MMP-9 expression, also has an
influence (Vaday et al. 2001).
In TNFR1 KO mice, macrophage infiltration, increased
TGF-β1 and enhanced α-SMA activity were noted. But no
cells showing co-positivity with GFP staining were con-
firmed in F4/80 immunohistochemistry. We think the
increase in macrophage came from recipient macrophage.
In addition, as a result, other inflammatory signals such as
TGF-β1 increased, followed by enhanced stellate cell
activity and increased liver fibrosis (Parsons et al. 2007;
Moreira 2007). DNA-Chip analysis also showed that the
macrophage-related gene such as “monocyte-macrophage
differentiation, MMD” was activated in TNFR1 KO mice
by bone marrow cell infusion (data not shown). Several
reports have evaluated the relationship between infiltrating
macrophages in the liver with hepatotoxicity, liver fibrosis
and liver regeneration (Liu et al. 2010; Duffield et al. 2005;
Tacke et al. 2009). An association between intrahepatic
macrophages with liver fibrolysis has also been reported
(Fallowfield et al. 2007). Based on the present study, after
BMC infusion in TNFR1 KO recipients, macrophages
infiltrating the liver enhanced the above-mentioned inflam-
matory responses and increased liver fibrosis. In conclu-
sion, proper TNFR1 signaling might be a key factor to
induce the improvement of liver fibrosis by bone marrow
cell infusion. Further studies will be needed to understand
the precise mechanism.
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